Catalyst Pharmaceuticals and Novavax have had tough go of it in May. Could better days be close at hand?
News & Analysis: Catalyst Pharmaceuticals
But serious questions remain about potential competition from a newly approved rival drug.
Catalyst posted outstanding first-quarter numbers this morning, but the good times may not last.
CPRX earnings call for the period ending March 31, 2019.
The drugmaker is rebounding after a big plunge earlier this week that might have been a little overdone.
Catalyst's shares are in free fall today after the FDA's surprise approval of a rival LEMS medication.
Catalyst's new orphan drug is off to a strong start.
These biotech stocks could have a lot of room to run.
The drugmaker's Q4 earnings release was a big hit with investors.
CPRX earnings call for the period ending December 31, 2018.